Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Positive H. Pylori status;~* Presence of upper gastro-intestinal symptoms;~* Mental and legal ability to sign informed consent.~Exclusion Criteria:~* Previous surgery of the GI tract;~* Clinically significant impairment of renal or hepatic function;~* Severe unstable cardiovascular, pulmonary or endocrine disease;~* Barrett's oesophagus or high-grade dysplasia;~* Dysphagia or vomiting as major symptoms.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OAC 7 days (Type: ACTIVE_COMPARATOR): Triple therapy, given for 7 days at a dose of omeprazole 20 mg twice daily, amoxicillin 500 mg 2 capsules twice daily, and clarithromycin 500 mg 1 tablet twice daily
- OBMT 10 days (Type: EXPERIMENTAL): OBMT (Pylera), consisting of a 3 in 1 capsule, made of bismuth subcitrate potassium 120 mg, metronidazole 125 mg, and tetracycline 125 mg, administered as 3 capsules 4 times daily. Omeprazole 20 mg is administered twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).